HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Abivertinib inhibits megakaryocyte differentiation and platelet biogenesis.

Abstract
Abivertinib, a third-generation tyrosine kinase inhibitor, is originally designed to target epidermal growth factor receptor (EGFR)-activating mutations. Previous studies have shown that abivertinib has promising antitumor activity and a well-tolerated safety profile in patients with non-small-cell lung cancer. However, abivertinib also exhibited high inhibitory activity against Bruton's tyrosine kinase and Janus kinase 3. Given that these kinases play some roles in the progression of megakaryopoiesis, we speculate that abivertinib can affect megakaryocyte (MK) differentiation and platelet biogenesis. We treated cord blood CD34+ hematopoietic stem cells, Meg-01 cells, and C57BL/6 mice with abivertinib and observed megakaryopoiesis to determine the biological effect of abivertinib on MK differentiation and platelet biogenesis. Our in vitro results showed that abivertinib impaired the CFU-MK formation, proliferation of CD34+ HSC-derived MK progenitor cells, and differentiation and functions of MKs and inhibited Meg-01-derived MK differentiation. These results suggested that megakaryopoiesis was inhibited by abivertinib. We also demonstrated in vivo that abivertinib decreased the number of MKs in bone marrow and platelet counts in mice, which suggested that thrombopoiesis was also inhibited. Thus, these preclinical data collectively suggested that abivertinib could inhibit MK differentiation and platelet biogenesis and might be an agent for thrombocythemia.
AuthorsJiansong Huang, Xin Huang, Yang Li, Xia Li, Jinghan Wang, Fenglin Li, Xiao Yan, Huanping Wang, Yungui Wang, Xiangjie Lin, Jifang Tu, Daqiang He, Wenle Ye, Min Yang, Jie Jin
JournalFrontiers of medicine (Front Med) Vol. 16 Issue 3 Pg. 416-428 (Jun 2022) ISSN: 2095-0225 [Electronic] China
PMID34792736 (Publication Type: Journal Article)
Copyright© 2021. Higher Education Press.
Chemical References
  • Acrylamides
  • Piperazines
  • Pyrimidines
  • abivertinib
Topics
  • Acrylamides (pharmacology)
  • Animals
  • Blood Platelets (cytology, drug effects)
  • Cell Differentiation
  • Megakaryocytes (cytology, drug effects)
  • Mice
  • Mice, Inbred C57BL
  • Piperazines (pharmacology)
  • Pyrimidines (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: